Cargando…
Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101)
BACKGROUND: Human epidermal growth factor (HER) 2 positivity and its association with clinicopathological factors remain unclear in Japanese gastric cancer (GC) patients. We performed a prospective, multicenter, observational cohort study to evaluate HER2 protein expression and gene amplification in...
Autores principales: | Matsusaka, Satoshi, Nashimoto, Atsushi, Nishikawa, Kazuhiro, Miki, Akira, Miwa, Hiroto, Yamaguchi, Kazuya, Yoshikawa, Takaki, Ochiai, Atsushi, Morita, Satoshi, Sano, Takeshi, Kodera, Yasuhiro, Kakeji, Yoshihiro, Sakamoto, Junichi, Saji, Shigetoyo, Yoshida, Kazuhiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Japan
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4906061/ https://www.ncbi.nlm.nih.gov/pubmed/26265390 http://dx.doi.org/10.1007/s10120-015-0518-8 |
Ejemplares similares
-
Erratum to: Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101)
por: Matsusaka, Satoshi, et al.
Publicado: (2015) -
Phase II study of the effectiveness and safety of trastuzumab and paclitaxel for taxane‐ and trastuzumab‐naïve patients with HER2‐positive, previously treated, advanced, or recurrent gastric cancer (JFMC45‐1102)
por: Nishikawa, Kazuhiro, et al.
Publicado: (2016) -
Randomized phase III trial comparing surgery alone to UFT + PSK for stage II rectal cancer (JFMC38 trial)
por: Okuno, Kiyotaka, et al.
Publicado: (2017) -
Randomized phase II study of daily and alternate-day administration of S-1 for advanced gastric cancer (JFMC43-1003)
por: Tanaka, Hiroaki, et al.
Publicado: (2017) -
Hazard rate of tumor recurrence over time in patients with colon cancer: implications for postoperative surveillance from three Japanese Foundation for Multidisciplinary Treatment of Cancer (JFMC) clinical trials
por: Maeda, Hiromichi, et al.
Publicado: (2017)